Shares of EyePoint Pharmaceuticals EYPT were flat in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 45.00% year over year to ($0.11), which missed the estimate of ($0.10).
Revenue of $7,489,000 higher by 272.22% year over year, which beat the estimate of $7,250,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 06, 2020
Webcast URL: https://edge.media-server.com/mmc/p/wmbgnxa6
Technicals
52-week high: $2.69
52-week low: $0.70
Price action over last quarter: down 30.08%
Company Profile
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
